Search

Your search keyword '"Goeminne J. -C."' showing total 6 results
Start Over Author "Goeminne J. -C." Publisher elsevier b.v.
6 results on '"Goeminne J. -C."'

1. 772 Which factors predict overall survival in metastatic castration-resistant prostate cancer patients treated with abiraterone acetate post-docetaxel?

Author

Van Praet, C., Rottey, S., Van Hende, F., Pelgrims, G., Demey, W., Van Aelst, F., Wynendaele, W., Gil, T., Schatteman, P., Filleul, B., Schallier, D., Machiels, J-P., Schrijvers, D., Everaert, E., D'Hondt, L., Werbrouck, P., Vermeij, J., Mebis, J., Clausse, M., Rasschaert, M., Van Erps, J., Verheezen, J., Van Haverbeke, J., Goeminne, J-C., and Lumen, N.

Published
2016
Full Text
View/download PDF

2. 257P Spatial predictors of pathologic complete response to neoadjuvant chemotherapy using imaging mass cytometry in the IMMUcan TNBC cohort.

Author

Garcia, A.J., Rediti, M., Morfouace, M., Venet, D., Eling, N., Schulz, D., Daniel, M., Déglise, S., Fernandez, B. Palau, Bodenmiller, B., Liechti, R., Marzetta, F., Penel, N., Oliveira, J., Goeminne, J-C., Fournel, P., Hong, H.S., Cesaroni, M., Sotiriou, C., and Buisseret, L.

Subjects
*PATHOLOGIC complete response, *NEOADJUVANT chemotherapy, *CYTOMETRY
Published
2024
Full Text
View/download PDF

3. 1621P Efficacy and safety of erdafitinib in adults with pancreatic cancer and prespecified fibroblast growth factor receptor alterations (FGFRalt) in the phase II open-label: Single-arm RAGNAR trial.

Author

Pant, S., Arnold, D., Tabernero, J., Loriot, Y., Folprecht, G., Haag, G.M., Palmer, D., Prenen, H., Coward, J., Lugowska, I., Goeminne, J-C., Cervantes, A., Gutierrez, M., Sweiti, H., Hammond, C., Najmi, S., Thomas, S., Triantos, S., Crow, L., and Schuler, M.H.H.

Subjects
*FIBROBLAST growth factor receptors, *CANCER patients, *PANCREATIC cancer
Published
2023
Full Text
View/download PDF

4. 1265MO Cause and place of death in older patients with cancer: Results from a large cohort study using linked clinical and population-based data.

Author

Depoorter, V., Vanschoenbeek, K., Decoster, L., De Schutter, H., Debruyne, P.R., De Groof, I., Bron, D., Cornelis, F., Luce, S., Focan, C., Verschaeve, V., Debugne, G., Langenaeken, C.M., van den Bulck, H.F.M., Goeminne, J-C., Milisen, K., Flamaing, J., Kenis, C., Verdoodt, F., and Wildiers, H.

Subjects
*OLDER patients, *CANCER patients, *COHORT analysis
Published
2022
Full Text
View/download PDF

5. Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkers.

Author

Seront, E., Rottey, S., Sautois, B., Kerger, J., D'Hondt, L. A., Verschaeve, V., Canon, J.-L., Dopchie, C., Vandenbulcke, J. M., Whenham, N., Goeminne, J. C., Clausse, M., Verhoeven, D., Glorieux, P., Branders, S., Dupont, P., Schoonjans, J., Feron, O., and Machiels, J.-P.

Subjects
*TRANSITIONAL cell carcinoma, *METASTASIS, *MOLECULAR biology, *RAPAMYCIN, *BIOMARKERS, *DRUG efficacy, *ORAL drug administration, *THERAPEUTICS
Abstract

Background This phase II study assessed the safety and efficacy of everolimus, an oral mammalian target of rapamycin inhibitor in advanced transitional carcinoma cell (TCC) after failure of platinum-based therapy. Patients and methods Thirty-seven patients with advanced TCC received everolimus 10 mg/day until progressive disease (PD) or unacceptable toxicity. The primary end point was the disease control rate (DCR), defined as either stable disease (SD), partial response (PR), or complete response at 8 weeks. Angiogenesis-related proteins were detected in plasma and changes during everolimus treatment were analyzed. PTEN expression and PIK3CA mutations were correlated to disease control. Results Two confirmed PR and eight SD were observed, resulting in a DCR of 27% at 8 weeks. Everolimus was well tolerated. Compared with patients with noncontrolled disease, we observed in patients with controlled disease a significant higher baseline level of angiopoietin-1 and a significant early plasma decrease in angiopoietin-1, endoglin, and platelet-derived growth factor-AB. PTEN loss was observed only in patients with PD. Conclusions Everolimus showed clinical activity in advanced TCC. The profile of the plasma angiogenesis-related proteins suggested a role of the everolimus antiangiogenic properties in disease control. PTEN loss might be associated with everolimus resistance. [ABSTRACT FROM AUTHOR]

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results